School of Medicine

Showing 1-10 of 29 Results

  • Myriam Amsallem

    Myriam Amsallem

    Postdoctoral Research Fellow, Cardiovascular Medicine

    Bio Dr. Myriam Amsallem, a cardiologist specialized in cardiac imaging, completed her training in Paris VII University, France. She has an interest in heart failure, cardioimmunology and early detection of pulmonary hypertension and right heart failure using imaging and circulating biomarkers. She is currently working on studies at Stanford University with Marie Lannelongue Hospital (French reference center for Pulmonary Hypertension, France) on studies on right heart remodeling with the goal of understanding the influence of inflammation and finding early biomarkers of remodeling. She also has a special interest in educational projects to improve the quality of imaging methodology.

  • Mohsen Fathzadeh

    Mohsen Fathzadeh

    Postdoctoral Research Fellow, Cardiovascular Medicine

    Bio My long-term goal is to learn, develop and design frameworks to implement “Precision Medicine” based on the “rare” and “common” genomic variants. Particularly, I am enthusiastic to construct global precision medicine basis to help individuals with diabetes, insulin resistance and cardiovascular comorbidity.
    After completing my master’s degree in human genetics, I was attracted by the fact that early onset coronary artery disease (CAD) manifest as a genetic subtype of the common type of CAD. In collaboration with Dr. Arya Mani and Dr. Richard Lifton, experts in Mendelian forms of CAD (Yale University), and Dr. Reza Malekzadeh, a pioneer of cohort studies (Tehran University), I contributed to the genetic analysis of families with early onset CAD and metabolic syndrome. We identified DYRK1B as a causative gene (co-first author; N Engl J Med; 2014).

    After completion of Ph.D. I was enthusiastic to be trained deeply on the genetic basis of diabetes and insulin resistance. Navigating through leading institutes, I found Stanford University an ideal place for this training; because here at Stanford Cardiovascular medicine, Dr. Gerald Reaven, a pioneer of insulin resistance, along with Drs. Thomas Quertermous and Joshua Knowles had developed the multicenter cohort for a GWAS of insulin resistance by direct measures of insulin sensitivity including “clamp-based” measures of insulin resistance. This group had just identified and validated a common SNP (rs1208, 803A>G, K268R) in N-acetyltransferase 2 (NAT2) as insulin resistance variant. In this innovative training and career development, I am taking part in defining the role of Nat1 (mouse ortholog of NAT2) in the global and liver specific knockout mice. We have already profiled ‘OMICs changes in the Nat1 global knockout mice with insulin resistance and extensively analyzed the data with promising finding on possible mechanism of mitochondria substrate availability and cholesterol biosynthesis.

    During postdoctoral fellowship, I have been involved in the joint project of Stanford-Merck on functional characterization of lipodystrophy-like genes identified through GWAS of glycemic traits (fasting insulin, HDL and WHR adjusted for BMI). This study has opened up new possibility and insight to target peripheral adiposity and insulin resistance. We extensively have been studying one of these promising targets in the transgenic mice and in the data from human cohorts.